deferiprone has been researched along with Anemia, Congenital Hypoplastic, Of Blackfan And Diamond in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy." | 7.74 | Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007) |
| " The report by Lecornec and colleagues offers useful details on indications and the management of deferiprone, a highly efficient chelator in removing excess cardiac iron but associated with a high risk of agranulocytosis in DBA patients." | 4.12 | Diamond-Blackfan anaemia with iron overload: A serious issue. ( Fagioli, F; Quarello, P; Ramenghi, U, 2022) |
| "Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and deferiprone." | 3.91 | Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. ( Gallie, BL; Olivieri, NF; Sabouhanian, A, 2019) |
| "A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy." | 3.74 | Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lecornec, N | 1 |
| Castex, MP | 1 |
| Réguerre, Y | 1 |
| Moreau, P | 1 |
| Marie, I | 1 |
| Garçon, L | 1 |
| Da Costa, L | 1 |
| Leblanc, T | 1 |
| Quarello, P | 1 |
| Ramenghi, U | 1 |
| Fagioli, F | 1 |
| Olivieri, NF | 1 |
| Sabouhanian, A | 1 |
| Gallie, BL | 1 |
| Henter, JI | 1 |
| Karlén, J | 1 |
4 other studies available for deferiprone and Anemia, Congenital Hypoplastic, Of Blackfan And Diamond
| Article | Year |
|---|---|
Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Deferiprone; Humans; Iron Overload; Retrospective Studies | 2022 |
Diamond-Blackfan anaemia with iron overload: A serious issue.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Chelating Agents; Deferiprone; Humans; Iron; Iron Overloa | 2022 |
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Topics: Administration, Oral; Anemia, Diamond-Blackfan; beta-Thalassemia; Blood Transfusion; Deferasirox; De | 2019 |
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Blood Cell Count; Bone Marrow; Child; Contraindications; | 2007 |